Brasada Capital Management LP Makes New $3.51 Million Investment in Cellebrite DI Ltd. $CLBT

Key Points

• Brasada Capital Management LP has invested approximately $3.51 million in Cellebrite DI Ltd. by acquiring 197,713 shares, representing 0.08% of the company's stock.
• During the first quarter, several hedge funds increased their holdings in Cellebrite DI, with T. Rowe Price acquiring a new position worth $60.94 million.
• Cellebrite DI reported $0.12 earnings per share for the most recent quarter, exceeding analysts' expectations, and its revenue grew by 18.4% year-over-year, amounting to $113.28 million.

Brasada Capital Management LP bought a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 197,713 shares of the company's stock, valued at approximately $3,509,000. Brasada Capital Management LP owned approximately 0.08% of Cellebrite DI at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Voss Capital LP lifted its stake in Cellebrite DI by 18.6% in the first quarter. Voss Capital LP now owns 3,843,602 shares of the company's stock valued at $74,681,000 after buying an additional 603,602 shares during the last quarter. Invesco Ltd. grew its holdings in Cellebrite DI by 122.1% during the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock worth $64,043,000 after acquiring an additional 1,811,757 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in Cellebrite DI in the first quarter valued at $60,939,000. Two Sigma Advisers LP increased its stake in Cellebrite DI by 35.0% in the 4th quarter. Two Sigma Advisers LP now owns 1,811,100 shares of the company's stock valued at $39,899,000 after purchasing an additional 470,000 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its stake in Cellebrite DI by 749.9% in the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after purchasing an additional 1,340,000 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Trading Down 0.2%

CLBT stock traded down $0.04 during mid-day trading on Tuesday, reaching $16.36. 1,600,435 shares of the stock traded hands, compared to its average volume of 2,341,530. The company has a market cap of $3.92 billion, a P/E ratio of 48.24, a P/E/G ratio of 2.98 and a beta of 1.28. Cellebrite DI Ltd. has a 52-week low of $13.10 and a 52-week high of $26.30. The stock's fifty day moving average is $15.01 and its 200-day moving average is $17.10.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. The business had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. Cellebrite DI's revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

CLBT has been the topic of several research reports. Needham & Company LLC lowered their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Lake Street Capital lowered their target price on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.